| Title | Diagnostic role of nuclear medicine in dilated cardiomyopathy | |
| Authors | Nikolaos Boussios¹, Evaggelos Karathanos¹, Adina Thomaidi² and Athanassios Zissimopoulos¹
1. Department of Nuclear Medicine and 2. University Cardiology Department, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece |
|
| Citation | Boussios, N., Karathanos, E., Thomaidi, A., Zissimopoulos, A.: Diagnostic role of nuclear medicine in dilated cardiomyopathy, Epitheorese Klin. Farmakol. Farmakokinet. 25(2): 55-58 (2011) | |
| Publication Date | Accepted for publication (Final version): July 1, 2011 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Dilated cardiomyopathy, myocardial perfusion imaging, radionuclide ventriculography, 123I-MIBG scintigraphy, BMIPP scintigraphy. | |
| Other Terms | review article | |
| Summary | Cardiomyopathies are primary diseases of the heart muscle associated with systolic heart failure. Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy and occurs at any age. It is often difficult to distinguish clinically between ischemic and non-ischemic DCM. Nuclear imaging methods, such as myocardial perfusion imaging and radionuclide ventriculography, are non-invasive tests often used for the above differential diagnosis. Iodine-123 metaiodobenzylguanidine (MIBG) scintigraphy can be useful in predicting treatment response and subsequent prognosis in patients with DCM and congestive heart failure and could help in selecting appropriate candidates for heart transplantation. Beta-methyl-p-[123I]-iodophenylpentadecanoic acid (BMIPP) scintigraphy is an emerging technique for imaging myocardial fatty acid metabolism. Myocardial metabolic abnormality evaluated by 123I-BMIPP scintigraphy is related to the severity of congestive heart failure. Furthermore, it may be useful as a predictor for cardiac events in patients with DCM. | |
| References | 1. Kyriakou P., Kyriakou Ch.: Idiopathic Dilated Cardio-myopathy: Epidemiology, Classification, and Pathogenesis. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 28: 97-112 (2010)
2. Kanonidis I.: Pharmaceutical treatment of heart failure. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 28: 187-192 (2010) 3. Taylor M.R., Carniel E., Mestroni L.: Cardiomyopathy, familial dilated. Orphanet. J. Rare Dis. 1: 27 (2006) 4. Johnson R.A., Palacios I.: Dilated cardiomyopathy of the adult. N. Engl. J. Med. 307:1051-1058, 1119-1126 (1982) 5. Hoffmeister H.M., Riesner C., Muller S.W., Karsch K.R.: Myocardial pattern of thallium-201 distribution in patients with dilated cardiomyopathy. Am. J. Non-invasive Cardiol. 5:235-239 (1991) 6. Saltissi S., Hockings B., Croft D.N., Webb P.M.: Thallium-201 myocardial imaging in patients with dilated and ischemic cardiomyopathy. Br. Heart J. 46: 290-295 (1981) 7. Dunn R.F., Uren R.F., Sadick N., et al.: Comparison of thallium-201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 66: 804-810 (1982) 8. Iskandrian A.S., Hakki A.H., Kane S.: Resting thallium-201 myocardial perfusion patterns in patients with severe left ventricular dysfunction: Differences between patients with primary cardiomyopathy, chronic coronary artery disease, or acute myocardial infarction. Am. Heart J. 111: 760-767 (1986) 9. Tauberg S.G., Orie J.E., Bartlett B.E., et al.: Usefulness of thallium-201 for distinction of ischemic from idiopathic dilated cardiomyopathy. Am. J. Cardiol. 71: 674-680 (1993) 10. Schwarz F., Mall G., Zebe H., et al.: Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 51: 501-506 (1983) 11. Greenberg J.M., Murphy J.H., Okada R.D., et al.: Value and limitations of radionuclide angiography in determining the cause of reduced left ventricular ejection fraction: Comparison of idiopathic dilated cardiomyopathy and coronary artery disease. Am. J. Cardiol. 55: 541-544 (1985) 12. Juilliere Y., Marie P.Y., Danchin N., et al.: Radionuclide assessment of regional differences in left ventricular wall motion and myocardial perfusion in idiopathic dilated cardiomyopathy. Eur. Heart J. 14: 1163-1169 (1993) 13. Gerwitz H., Grötte G., Strauss H., et al.: The influence of left ventricular volume and wall motion on myocardial images. Circulation 59: 1172-1177 (1979) 14. Tamai J., Nagata S., Nishimura T., et al.: Hemodynamic and prognostic value of thallium-201 myocardial imaging in patients with dilated cardiomyopathy. Int. J. Cardiol. 24: 219-224 (1989) 15. Takata J., Doi Y., Yonezawa Y., et al.: Prognostic significance of perfusion defect and its extension in dilated cardiomyopathy: Assessment with thallium-201 myocardial scintigraphy. J. Cardiol. 21: 915-922 (1991) 16. Juilliere Y., Marie P.Y., Danchin N., et al.: Serial evaluation of dilated cardiomyopathy with exercise thallium-201 tomography: Correlation with the evolution of left ventricular parameters. Int. J. Cardiol. 46: 159-167 (1994) 17. Moralidis E., Karakatsanis C.: Nuclear cardiology in the differentiation of ischemic from non-ischemic dilated cardiomyopathy. Rev. Clin. Pharmacol. Pharmacokinet. 28: 145-149 (2010) 18. Allman K.C., Lahiri A.: I-123 MIBG scintigraphy in idiopathic dilated cardiomyopathy: Where next? J. Nucl. Cardiol. 9: 127-130 (2002) 19. Merlet P., Benvenuti C., et al.: Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J. Nucl. Med. 40: 917-923 (1999) 20. Packer M., Bristow M.R., Cohn J.N., et al., for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patient with chronic heart failure. N. Engl. J. Med. 334: 1349-1355 (1996) 21. Knapp F.K., Ambrose K.R., Goodman M.M.: New radioiodinated methyl-branched fatty acids for cardiac studies. Eur. J. Nucl. Med. 12: S39-S44 (1986) 22. Ogata M.: Myocardial uptake of 125I-BMIPP in rats treated with adriamycin. Jpn J. Nucl. Med. 26: 69-76 (1989) 23. Yongih Kim, Sawada Y., et al.: Therapeutic effect of co-enzyme Q10 in idiopathic dilated cardiomyopathy: assessment by iodine-123-labelled-15-(p-iodophenyl)-3-(R,S) methyl pentadecanoic acid myocardial SPECT. Eur. J. Nucl. Med. 24: 629-634 (1997) 24. Hosokawa R., Nohara R., Fujibayashi Y., et al.: Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: Implications for clinical SPECT. J. Nucl. Med. 38: 1857-1863 (1997) 25. Narita M., Kurihara T.: Fatty acid metabolism in patients with idiopathic dilated cardiomyopathy: Characteristics and prognostic implications. J. Cardiol. 25: 223-231 (1995) 26. Nakae I., Mitsunami K., Matsuo S., Horie M.: Creatine Depletion and Altered Fatty Acid Metabolism in Diseased Human Hearts: Clinical Investigation Using 1H Magnetic Resonance Spectroscopy and 123I BMIPP Myocardial Scintigraphy. Acta Radiologica 48: 436-443 (2007) |
|
| Relative Papers |
Online ISSN 1011-6575